Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I intradermal HPV16 E7 DNA vaccination in HPV16-positive vulvar intraepithelial neoplasia
NL-OMON40423Phase 1Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2014
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of TTFC-E7SH in vulvar intraepithelial neoplasia (VIN) (2 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and toxicity of TTFC-E7SH at two dose levels and HPV-specific immune response. Started Jun 2014; status: active, not recruiting.
02
Drugs
TTFC-E7SH
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NL-OMON40423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40423.